文献速递冠心病

STREAM-2:老年STEMI患者半剂量替奈普酶药物侵入策略与直接PCI的随机对照研究

STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
PubMed 文献 · Circulation · 2023-07-13

STREAM-2为随机、开放标签、多中心研究,纳入≥60岁、无法在1小时内行直接PCI的STEMI患者,按2:1随机接受半剂量替奈普酶后6-24小时冠脉造影及必要时PCI(药物侵入策略,n=401)或直接PCI(n=203)。两组30天死亡、休克、心衰或再梗复合终点发生率相似(12.8% vs 13.3%,RR 0.96,95%CI 0.62-1.48),药物侵入策略颅内出血发生率1.5%,直接PCI组为0。

要点

  • 半剂量替奈普酶药物侵入策略的30天临床复合终点与直接PCI相似。
  • 药物侵入策略颅内出血发生率为1.5%,直接PCI组无颅内出血。
  • 无法及时行直接PCI时,半剂量替奈普酶药物侵入策略是合理替代方案。

核心结论

  • 在早期就诊的老年STEMI患者中,半剂量替奈普酶药物侵入策略的心电图改变至少与直接PCI相当,临床疗效和造影终点相似。
  • 半剂量替奈普酶药物侵入策略的颅内出血风险高于直接PCI。
  • 无法及时行PCI时,该药物侵入策略是合理替代方案,但需遵守纤溶禁忌并避免过量抗凝。

研究设计与样本

  • STREAM-2为研究者发起的随机、开放标签、多中心研究。
  • 纳入≥60岁、2个相邻导联ST段抬高≥2 mm、无法在1小时内行直接PCI的STEMI患者。
  • 按2:1随机分配至半剂量替奈普酶后6-24小时冠脉造影及必要时PCI组(n=401)或直接PCI组(n=203)。

主要发现

  • 随机至替奈普酶或鞘管置入的中位时间分别为10分钟和81分钟。
  • 末次造影后,药物侵入策略组85.2%、直接PCI组78.4%的患者ST段抬高缓解≥50%。
  • 末次造影ST偏差中位总和分别为4.5 mm和5.5 mm。
  • 末次造影TIMI 3级血流两组均约87%。
  • 30天死亡、休克、心衰或再梗复合终点发生率分别为12.8%(51/400)和13.3%(27/203),RR 0.96(95%CI 0.62-1.48)。

关键数值与推荐

  • 药物侵入策略组发生6例颅内出血(1.5%),其中3例为方案违背(2例过量抗凝、1例未控制高血压)。
  • 直接PCI组无颅内出血。
  • 两组大非颅内出血发生率均较低(<1.5%)。

临床怎么用

  • 对于无法在1小时内行直接PCI的老年STEMI患者,可考虑半剂量替奈普酶药物侵入策略。
  • 实施该策略前需确认无纤溶禁忌证。
  • 应避免过量抗凝以降低颅内出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ST-segment-elevation myocardial infarction (STEMI) guidelines recommend pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is unavailable. Full-dose tenecteplase is associated with an increased risk of intracranial hemorrhage in older patients. Whether pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients with STEMI is unknown. METHODS: STREAM-2 (Strategic Reperfusion in Elderly Patients Early After Myocardial Infarction) was an investigator-initiated, open-label, randomized, multicenter study. Patients ≥60 years of age with ≥2 mm ST-segment elevation in 2 contiguous leads, unable to undergo primary PCI within 1 hour, were randomly assigned (2:1) to half-dose tenecteplase followed by coronary angiography and PCI (if indicated) 6 to 24 hours after randomization, or to primary PCI. Efficacy end points of primary interest were ST resolution and the 30-day composite of death, shock, heart failure, or reinfarction. Safety assessments included stroke and nonintracranial bleeding. RESULTS: Patients were assigned to pharmaco-invasive treatment (n=401) or primary PCI (n=203). Median times from randomization to tenecteplase or sheath insertion were 10 and 81 minutes, respectively. After last angiography, 85.2% of patients undergoing pharmaco-invasive treatment and 78.4% of patients undergoing primary PCI had ≥50% resolution of ST-segment elevation; their residual median sums of ST deviations were 4.5 versus 5.5 mm, respectively. Thrombolysis In Myocardial Infarction flow grade 3 at last angiography was ≈87% in both groups. The composite clinical end point occurred in 12.8% (51/400) of patients undergoing pharmaco-invasive treatment and 13.3% (27/203) of patients undergoing primary PCI (relative risk, 0.96 [95% CI, 0.62-1.48]). Six intracranial hemorrhages occurred in the pharmaco-invasive arm (1.5%): 3 were protocol violations (excess anticoagulation in 2 and uncontrolled hypertension in 1). No intracranial bleeding occurred in the primary PCI arm. The incidence of major nonintracranial bleeding was low in both groups (<1.5%). CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02777580.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Van de Werf, Ristić, Averkov, et al. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial. Circulation. 2023. PMID: 37439219. doi:10.1161/CIRCULATIONAHA.123.064521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。